View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 18, 2021updated 12 Jul 2022 11:06am

First patient dosed in BioNTech Phase II trial of mRNA cancer vaccine

Dosing has commenced in BioNTech's BNT111 Phase II cancer vaccine trial in advanced melanoma.

By Kezia Parkins

The first patient has been treated in a Phase II cancer vaccine trial by BioNTech, evaluating its mRNA-based therapy BNT111 in combination with Libtayo (cemiplimab) in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The open-label randomised trial will assess the efficacy, tolerability and safety of BNT111 in combination with Libtayo. It will enrol 120 patients and will evaluate the effects of the combination, as well as stand-alone individual agents.

BNT111 is the lead product candidate from BioNTech’s FixVac platform and targets a fixed combination of mRNA-encoded, tumour-associated antigens, with the aim of activating a strong and precise immune response against cancer.

The candidate is fully owned by BioNTech while Libtayo, an anti-PD-1 monoclonal antibody, is being co-developed by Regeneron and Sanofi.

“BNT111 is an intravenous therapeutic cancer vaccine candidate encoding for a fixed set of four cancer-specific antigens optimised for immunogenicity and delivered as RNA-lipoplex formulation,” says BIoNTech. According to the firm, more than 90% of melanomas in patients express at least one of the four tumour-associated antigens encoded in BNT11; NY-ESO-1, MAGE-A3, tyrosinase and TPTE.

The BNT111-01 trial, which is being carried out in collaboration with Regeneron, was reviewed and approved by the regulatory authorities in EU countries Spain, Germany, Italy and Poland as well as in the UK, the US and Australia. The first patient has been dosed in the EU.

The primary endpoint of the study is to assess the overall response rate of BNT111 in combination with Libtayo. Secondary endpoints include overall response rate in the single-agent arms, duration of response and safety.

“Our vision is to harness the power of the immune system against cancer and infectious diseases. We were able to demonstrate the potential of mRNA vaccines in addressing Covid-19. We must not forget, that cancer is also a global health threat, even worse than the current pandemic,” said BioNTech’s co-founder and CMO Özlem Türeci.

“BNT111 has already shown a favourable safety profile and encouraging preliminary results in early clinical evaluation. With the start of patient treatment in our Phase II trial, we are encouraged to continue on our initial path to realise the potential of mRNA vaccines for cancer patients.”

This Phase II trial is based on previous results from the Phase I Lipo-MERIT dose-escalation trial that confirmed a favourable safety profile in 89 patients with advanced melanoma. Additionally, efficacy analysis of the Lipo-MERIT study in a subset of 42 metastatic melanoma patients treated earlier with a checkpoint-inhibitor demonstrated that BNT111 mediated durable responses, both as a single agent and in combination with anti-PD-1 antibodies. Durable objective responses by BNT111 were associated with activation and strong expansion of tumor-antigen-specific CD4+ and CD8+ T cells. These results were published in Nature in July 2020.

BioNTech also plans to start randomised Phase II trials with mRNA vaccine product candidates in two additional programs in 2021.

“As part of its development strategy, BioNTech aims to rapidly advance its broad oncology pipeline and expects to bring additional candidates into late-stage clinical development and towards market entry within the next five years,” said the firm.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena